Suspect COVID-19 is a vascular disease?

Recently, a research team from the RWTH Aachen Medical School in Germany published an article in THE LANCET Regional Health-Europe, announcing the largest autopsy case study of the new crown to date

At the same time, we found another research article published in the leading cardiovascular journal Hypertension

The researchers aimed to study the use of angiotensin-converting enzyme inhibitors (ACE) and angiotensin receptor blockers compared to calcium channel blockers (CCBs)

Whether the risk of COVID-19 infection in patients receiving antihypertensive drugs (ARBs) varies by class of antihypertensive drugs

From February 15, 2020, to June 7, 2020, the researchers followed 3 cohorts of ACE inhibitor, ARB and CCB users aged 18-80 years in the French National Health Insurance database

The researchers excluded patients with a history of diabetes, cardiovascular disease, chronic renal failure, or chronic respiratory disease within the past 5 years, and only considered patients without concurrent hypertension

The primary endpoint of the study was hospital stay for COVID-19

Of the nearly 2 million hypertensive patients, 2338 were hospitalized for COVID-19 and 526 died or were intubated during a 16-week follow-up

ACE inhibitor users and ARB users had a lower risk of COVID-19 hospitalization than CCB users (hazard ratio, 0.

This large observational study may suggest that long-term ACE inhibitors or ARBs in hypertensive patients have a lower risk of COVID-19 compared with CCBs

refer to:

https://doi.